Integral Diagnostics Ltd. (AU:IDX)
ASX:IDX
Want to see AU:IDX full AI Analyst Report?
IDX Stock Chart & Stats
AU$2.26
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$2.26
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$2.00 - AU$3.07
Previous CloseN/A
Volume920.11K
Average Volume (3M)911.20K
Market Cap
AU$768.08M
Enterprise ValueAU$1.62B
Total Cash (Recent Filing)AU$34.12M
Total Debt (Recent Filing)AU$841.54M
Price to Earnings (P/E)53.7
Beta0.53
Next Earnings
Aug 25, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend Yield2.65%
Share Statistics
EPS (TTM)0.03
Shares Outstanding373,066,530
10 Day Avg. Volume1,057,226
30 Day Avg. Volume911,197
Financial Highlights & Ratios
PEG Ratio-1.57
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio55.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.14Price Target Upside38.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.13
Revenue Forecast (FY)AU$801.35M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRevenue growth above 50% demonstrates durable demand expansion across IDX's network. Sustained top-line growth supports scale benefits for fixed-cost imaging equipment and clinics, enabling broader service coverage and potential market-share gains if utilization and referral patterns persist.
Very High Gross MarginsA gross margin of 95.52% indicates efficient delivery of imaging and reporting services and strong margin capture on service revenue. High gross margins create structural capacity to absorb SG&A, fund reinvestment in equipment and clinics, and protect profitability against modest pricing or volume fluctuations.
Improved Leverage / Stable Equity BaseA lower debt-to-equity ratio (0.84) and stable equity ratio reduce solvency risk and improve financial flexibility. This stronger balance-sheet position supports multi-month capital deployment for equipment refreshes or selective expansion while offering resilience against revenue volatility.
Bears Say
Very Low Net Profit MarginA net margin of 0.75% shows limited conversion of revenue into earnings, constraining retained cash and shareholder returns. Persistently low net profitability heightens sensitivity to reimbursement cuts, staffing or supply cost increases, and limits capacity to self-fund strategic investments over months.
Declining Free Cash FlowA nearly 59% decline in free cash flow signals weakening cash conversion despite positive operating cash flow. Reduced FCF limits ability to fund capex for scanners, service expansions or debt servicing, increasing reliance on external funding and raising liquidity risk over the next several quarters.
Very Low Return On EquityROE of 0.67% reflects weak shareholder returns and inefficient capital deployment relative to growth. Low ROE suggests growth has not translated into profitable use of equity, which can deter long-term investor support and constrain financial levers for strategic initiatives.
Integral Diagnostics Ltd. News
IDX FAQ
What was Integral Diagnostics Ltd.’s price range in the past 12 months?
Integral Diagnostics Ltd. lowest share price was AU$2.00 and its highest was AU$3.07 in the past 12 months.
What is Integral Diagnostics Ltd.’s market cap?
Integral Diagnostics Ltd.’s market cap is AU$768.08M.
When is Integral Diagnostics Ltd.’s upcoming earnings report date?
Integral Diagnostics Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 81 days.
How were Integral Diagnostics Ltd.’s earnings last quarter?
Integral Diagnostics Ltd. released its earnings results on Feb 23, 2026. The company reported AU$0.024 earnings per share for the quarter, missing the consensus estimate of AU$0.056 by -AU$0.032.
Is Integral Diagnostics Ltd. overvalued?
According to Wall Street analysts Integral Diagnostics Ltd.’s price is currently Undervalued.
Does Integral Diagnostics Ltd. pay dividends?
Integral Diagnostics Ltd. pays a Semiannually dividend of AU$0.04 which represents an annual dividend yield of 2.65%. See more information on Integral Diagnostics Ltd. dividends here
What is Integral Diagnostics Ltd.’s EPS estimate?
Integral Diagnostics Ltd.’s EPS estimate is 0.07.
How many shares outstanding does Integral Diagnostics Ltd. have?
Integral Diagnostics Ltd. has 373,066,530 shares outstanding.
What happened to Integral Diagnostics Ltd.’s price movement after its last earnings report?
Integral Diagnostics Ltd. reported an EPS of AU$0.024 in its last earnings report, missing expectations of AU$0.056. Following the earnings report the stock price went down -5.83%.
Which hedge fund is a major shareholder of Integral Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:IDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integral Diagnostics Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$3.14 (38.94% Upside)
AU$3.14 (38.94% Upside)
Blogger Sentiment
Bullish
AU:IDX Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$170.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.34%
12-Months-Change
Fundamentals
Return on Equity
2.05%
Trailing 12-Months
Asset Growth
4.81%
Trailing 12-Months
Company Description
Integral Diagnostics Ltd.
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. It provides services through 67 radiology clinics. The company was incorporated in 2008 and is headquartered in Melbourne, Australia.
IDX Stock 12 Month Forecast
Average Price Target
AU$3.14
▲(38.94% Upside)
Technical Analysis
Healius Limited
―
Genetic Signatures Ltd.
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―
Monash IVF Group Ltd
―
Options Prices
Currently, No data available
---